Moody's cuts Octapharma

Moody's Investors Service said it downgraded the issuer rating of Octapharma Nordic AB to Baa3 from Baa2.

Concurrently, Moody's said it also placed the Baa3 rating on review for possible downgrade.

The rating action follows the withdrawal and recall of Octapharma's key products octagam (50mg/ml) and octagam 10% (100mg/ml) that was requested by health care authorities in the United States and European market, the agency added.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.